歌礼制药宣布其针对肥胖症的超长效皮下储库型小分子GLP-1受体激动剂ASC30在美国开展的II期临床试验中取得积极顶线结果。该研究为期24周,评估了ASC30制剂的安全性与有效性。
歌礼制药宣布其针对肥胖症的超长效皮下储库型小分子GLP-1受体激动剂ASC30在美国开展的II期临床试验中取得积极顶线结果。该研究为期24周,评估了ASC30制剂的安全性与有效性。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.